Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-β1 in relation to disease activity in Crohn's disease patients

Annals of the New York Academy of Sciences

Volumn 1091, Issue , 2006, Pages 110-122

  Rezaie, Ali ^a   Ghorbani, Fakhteh ^a   Eshghtork, Azadeh ^a   Zamani, Mohammad J ^a   Dehghan, Gholamreza ^a   Taghavi, Bardia ^a   Nikfar, Shekoufeh ^a   Mohammadirad, Azadeh ^c   Daryani, Nasser E ^b   Abdollahi, Mohammad ^a,b  

^a Tehran University of Medical Science   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NONE

Author keywords

Crohn's disease; Disease activity index; Inflammatory bowel disease; Nitric oxide; Saliva; Salivary antioxidants; Transforming growth factor; Ulcerative colitis

Indexed keywords

ALBUMIN; ANTIOXIDANT; NITRIC OXIDE; THIOL; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1; URIC ACID;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; QUANTITATIVE ASSAY; SALIVA LEVEL; ADOLESCENT; ARTICLE; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SALIVA;

ADOLESCENT; ADULT; ANTIOXIDANTS; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; SALIVA; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33947609783     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1378.060     Document Type: Conference Paper

References (61)

1. REZAIE, A., B.T. BAYAT & M. ABDOLLAHI. 2005. Biologic management of fistulizing Crohn's disease. Int. J. Pharmacol. 1: 17-24.
2. PLAYFORD, R.J. & S. GHOSH. 2005. Cytokines and growth factor modulators in intestinal inflammation and repair. J. Pathol. 205: 417-425.
3. CROSS, R.K. & K.T. WILSON. 2003. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 9: 179-189.
4. WENDLAND, B.E., E. AGHDASSI, C. TAM, et al. 2001. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am. J. Clin. Nutr. 74: 259-264.
5. D'ODORICO, A., S. BORTOLAN & R. CARDIN. 2001. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand. J. Gastroenterol. 36: 1289-1294.
6. MIRALLES-BARRACHINA, O., G. SAVOYE, L. BELMONTE-ZALAR, et al. 1999. Low levels of glutathione in endoscopic biopsies of patients with Crohn's colitis: the role of malnutrition. Clin. Nutr. 18: 313-317.
7. ARDITE, E., M. SANS, J. PANES, et al. 2000. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest. 8: 735-744.
8. SIDO, B., V. HACK, A. HOCHLEHNERT, et al. 1998. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 42: 485-492.
9. HOLMES, E.W., S.L. YOUNG, D. EIZNHAMER & A. KESHAVARZIAN. 1998. Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig. Dis. Sci. 43: 1088-1095.
10. STURNIOLO, G.C., C. MESTRINER, P.E. LECIS, et al. 1998. Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. Scand. J. Gastroenterol. 33: 644-649.
11. GEERLING, B.J., A. BADART-SMOOK, C. VAN DEURSEN, et al. 2000. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm. Bowel Dis. 6: 77-84.
12. BUFFINGTON, G.D. & W.F. DOE. 1995. Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. Free Radic. Res. 22: 131-143.
13. D'ODORICO, A., F. POZZATO, M. MINOTTO, et al. 1996. Plasma carotenoids and other antioxidant levels in Crohn's disease. Gastroenterology 110: A897.
14. GEERLING, B.J., A. BADART-SMOOK, R.W. STOCKBRUGGER & R.J. BRUMMER. 1998. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am. J. Clin. Nutr. 67: 919-926.
15. SPITZ, D.R., E.I. AZZAM, J.J. LI & D. GIUS. 2004. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev. 23: 311-322.
16. KRUIDENIER, L. & H.W. VERSPAGET. 2002. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol. Ther. 16: 1997-2015.
17. KIMURA, H., S. MIURA, T. SHIGEMATSU, et al. 1997. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig. Dis. Sci. 42: 1047-1054.
18. LUETHVIKSSON, B.R. & B. GUNNLAUGSDOTTIR. 2003. Transforming growth factor-beta as a regulator of site-specific T-cell inflammatory response. Scand. J. Immunol. 58: 129-138.
19. BARTOLOME, R.A., F. SANZ-RODRIGUEZ, M.M. ROBLEDO, et al. 2003. Rapid upregulation of alpha4 integrin-mediated leukocyte adhesion by transforming growth factor-beta1. Mol. Biol. Cell 14: 54-66.
20. GORELIK, L. & R.A. FLAVELL. 2002. Transforming growth factor-beta in T-cell biology. Nat. Rev. 2: 46-53.
21. GARG, A.K. & B.B. AGGARWAL. 2002. Reactive oxygen intermediates in TNF signalling. Mol. Immunol. 39: 509-517.
22. DAHLY, A.J., K.M. HOAGLAND, A.K. FLASCH, et al. 2002. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R757-R767.
23. YING, W.Z. & P.W. SANDERS. 2003. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am. J. Physiol. Renal Physiol. 285: F902-F908.
24. JAHANSHAHI, G., V. MOTAVASEL, A. REZAIE, et al. 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci. 49: 1752-1757.
25. NAVAZESH, M. 1993. Methods for collecting saliva. Ann. N.Y. Acad. Sci. 694: 72-77.
26. KAUFMAN, E. & I.B. LAMSTER. 2000. Analysis of saliva for periodontal diagnosis - a review. J. Clin. Periodontol. 27: 453-465.
27. EDGAR, W.M. 1992. Saliva: its secretion, composition and functions. Br. Dent. J. 172: 305-312.
28. BEST, W.R., J.M. BECKTEL, J.W. SINGLETON & F. KERN JR. 1976. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444.
29. AGHDASSI, E. & J.P. ALLARD. 2000. Breath alkanes as a marker of oxidative stress in different clinical conditions. Free Radic. Biol. Med. 28: 880-886.
30. AFSHARI, M., B. LARIJANI, A. REZAIE, et al. 2004. Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacother. 58: 546-550.
31. AGHDASSI, E., B.E. WENDLAND & A.H. STEINHART, et al. 2003. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. A randomized controlled trial. Am. J. Gastroenterol. 98: 348-353.
32. MOHAMED, M.A., H. ROBERTSON, T.A. BOOTH, et al. 2000. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation 69: 1002-1005.
33. SATHO, K. 1978. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta 90: 37-43.
34. BENZIE, I.F.F. & J.J. STRAIN. 1996. Ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal. Biochem. 239: 70-76.
35. DUNCAN, P.H., N. GOCHMAN, T. COOPER, et al. 1982. A candidate reference method for uric acid in serum. I. Optimization and evaluation. Clin. Chem. 28: 284-290.
36. BUFFONE, G.J., S.A. LEWIS, M. IOSEFSOHN & J.M. HICKS. 1978. Chemical and immunochemical measurement of total iron-binding capacity compared. Clin. Chem. 24: 1788-1791.
37. DOUMAS, B.T., W.A. WATSON & H.G. BIGGS. 1971. Albumin standards and the measurement of serum albumin with bromcresol green. Clin. Chim. Acta 31: 87-96.
38. HU, M.L. & C.J. DILLARD. 1994. Plasma SH and GSH measurement. Methods Enzymol. 233: 385-387.
39. SINGER, I.I., D.W. KAWKA, S. SCOTT, et al. 1996. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111: 871-885.
40. DIJKSTRA, G., H. MOSHAGE, H.M. VAN DULLEMEN, et al. 1998. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J. Pathol. 186: 416-421.
41. SARAFIAN, T.A. & D.E. BREDESEN. 1994. Is apoptosis mediated by reactive oxygen species? Free Radic. Res. 21: 1-8.
42. PANJAMURTHY, K., S. MANOHARAN & C.R. RAMACHANDRAN. 2005. Lipid peroxidation and antioxidant status in patients with periodontitis. Cell Mol. Biol. Lett. 10: 255-264.
43. MILES, A.M. & M.B. GRISHAM. 1994. Antioxidant properties of aminosalicylates. Methods Enzymol. 234: 555-572.
44. MOORE, S., K.A. CALDER, N.J. MILLER & C.A. RICE-EVANS. 1994. Antioxidant activity of saliva and periodontal disease. Free Radic. Res. 21: 417-425.
45. GROOTVELD, M. & B. HALLIWELL. 1987. Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo? Biochem. J. 243: 803-808.
46. HALLIWELL, B. 1994. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.
47. GOULART, M., M.C. BATOREU, A.S. RODRIGUES, et al. 2005. Lipoperoxidation products and thiol antioxidants in chromium exposed workers. Mutagenesis 20: 311-315.
48. BALCERCZYK, A. & G. BARTOSZ. 2003. Thiols are main determinants of total antioxidant capacity of cellular homogenates. Free Radic. Res. 37: 537-541.
49. GILADI, E., E. RAZ, F. KARMELI, et al. 1995. Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats. Eur. J. Gastroenterol. Hepatol. 7: 341-347.
50. DIGNASS, A.U., J.L. STOW & M.W. BABYATSKY. 1996. Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta. Gut 38: 687-693.
51. BABYATSKY, M.W., G. ROSSITER & D.K. PODOLSKY. 1996. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984.
52. XIAN, C.J., X. XU, C.E. MARDELL, et al. 1999. Site-specific changes in transforming growth factor-alpha and beta1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Scand. J. Gastroenterol. 34: 591-600.
53. MAXWELL, L. & W. DOE. 2001. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm. Bowel Dis. 7: 16-26.
54. BECK, P.L. & D.K. PODOLSKY. 1999. Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. 5: 44-60.
55. KADER, H.A., V.T. TCHERNEV, E. SATYARAJ, et al. 2005. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am. J. Gastroenterol. 100: 414-423.
56. SPORN, M.B. & A.B. ROBERTS. 1992. Autocrine secretion-10 years later. Ann. Intern. Med. 117: 408-414.
57. STURM, A., C. SCHULTE, R. SCHATTON, et al. 2000. Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 12: 445-450.
58. RACHMILEWITZ, D., R. ELIAKIM, Z. ACKERMAN, et al. 1998. Direct determination of colonic nitric oxide level: a sensitive marker of disease activity in ulcerative colitis. Am. J. Gastroenterol. 93: 409-412.
59. KOEK, G.H., G.M. VERLEDEN, P. EVENEPOEL & P. RUTGEERTS. 2002. Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement? Respir. Med. 96: 530-535.
60. LJUNG, T., M. HERULF, E. BEIJER, et al. 2001. Rectal nitric oxide assessment in children with Crohn disease and ulcerative colitis. Indicator of ileocaecal and colorectal affection. Scand. J. Gastroenterol. 36: 1073-1076.
61. GUIHOT, G., R. GUIMBAUD, V. BERTRAND, et al. 2000. Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn's disease. Amino Acids 18: 229-237.